Company Overview
Snapshot
Founded in July 2015 by Aryeh Batt, Anthony Atala, and Shay Soker, Precise Bio operates with 11–50 employees. The company has raised $22 million across four funding rounds from four investors. In July 2022, Precise Bio announced a partnership with Carl Zeiss Meditec for the development and commercialization of tissue-based implants for ophthalmology.
Business overview
Precise Bio is a regenerative medicine company focused on advancing bio-printed tissues and organs, particularly for ophthalmology patients. The company's core technology is its 4D bio-fabrication platform, which integrates cell expansion, biomaterials, processes, and printing technology. This platform enables the development of fabricated human corneas and other organs and tissues, addressing challenges in scalable and reproducible manufacturing. Precise Bio serves the health tech and life sciences sectors, with offices and facilities in North Carolina, United States, and Shoham, Israel.
Strategic signal
In July 2022, Precise Bio formed a strategic partnership with Carl Zeiss Meditec for the development and commercialization of tissue-based implants for ophthalmology. This collaboration is a significant validation of Precise Bio's 4D bio-fabrication technology and signals a strong commercial pathway for its bio-printed cornea program, indicating potential for accelerated market entry and broader impact in regenerative medicine.
Log in to access full profile ›Company Intelligence Q&A
- What was a key strategic partnership for Precise Bio?
- In July 2022, Precise Bio announced a partnership with Carl Zeiss Meditec for the development and commercialization of tissue-based implants designed for ophthalmology.
- When did Precise Bio launch its dedicated ophthalmology business unit?
- Precise Bio announced the launch of its dedicated ophthalmology business unit in October 2018 at AAO 2018, coinciding with the opening of a new facility for developing 3D-printed corneas.
- What is Precise Bio's total disclosed funding?
- Precise Bio has raised a total of $22 million across four funding rounds. Notable investors include Carl Zeiss and Aurum Ventures M.K.I.
- Who were the co-founders of Precise Bio?
- Precise Bio was co-founded by Aryeh Batt, Anthony Atala, and Shay Soker in July 2015.
- What is Precise Bio's primary focus in regenerative medicine?
- Precise Bio is focused on advancing the use of bio-printed tissues and organs, with a particular emphasis on ophthalmology patients and developing a broad portfolio of R&D programs in additional medical disciplines.